Q: What is Lutathera used for?

Lutathera is used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors .

Q: How does Lutathera work?

Targeted Therapy Lutathera belongs to a class of drugs known as peptide receptor radionuclide therapy (PRRT). It works by combining a targeting molecule with a radioactive isotope to deliver treatment directly to cancer cells. How It Targets Cancer Many neuroendocrine tumors have a high number of proteins on their surface called somatostatin receptors. Lutathera is designed to recognize and bind specifically to these receptors. Once the drug attaches to the receptor, the cancer cell absorbs the medication. Destroying Tumor Cells After entering the cell, the radioactive part of the medicine, called lutetium-177, releases energy in the form of radiation. This radiation travels a short distance to damage the DNA within the tumor cell and nearby cells. This damage prevents the cancer cells from reproducing and eventually leads to cell death.

Q: What are the active ingredients in Lutathera?

The active ingredient in Lutathera is dotatate .

Q: What are the side effects of Lutathera?

Common side effects of Lutathera may include: Nausea Vomiting Fatigue and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Lutathera?

Lutathera belongs to the radiolabeled somatostatin analog drug class.

Q: What is the dosage of Lutathera and how do I take it?

Administration Lutathera is a radioactive drug given by a healthcare professional through an intravenous (IV) infusion into a vein. Because it contains radiation, it must be administered in a specialized facility, such as a nuclear medicine department or a radiology clinic, by staff trained in handling radioactive materials. Treatment Schedule The treatment usually consists of a series of infusions. These doses are spaced several weeks apart to allow the body to recover between treatments. Your healthcare provider will determine the exact schedule based on your specific condition and how you respond to the medication. Preparation and Supportive Care To help protect your kidneys and manage side effects, you will receive other medications along with Lutathera: Anti-nausea medication: You will receive medicine to help prevent nausea and vomiting before the infusion begins. Amino acid solution: You will receive an intravenous infusion of amino acids before, during, and after the Lutathera treatment. This solution helps protect your kidneys from the effects of radiation. Missed Doses If you miss an appointment for your infusion, contact your healthcare provider immediately to reschedule. It is important to follow the treatment timeline as closely as possible for the medication to be effective.

Q: Is Lutathera safe during pregnancy and breastfeeding?

Pregnancy Lutathera is a radiopharmaceutical that can cause harm to a fetus. Due to the risk of radiation exposure, healthcare providers will typically verify that a patient is not pregnant before starting treatment. If you are pregnant or become pregnant during treatment, it is important to discuss the potential risks to the fetus with your medical team. Patients of reproductive potential should use effective birth control during treatment and for a period of time after the final dose: Females: Use effective contraception during treatment and for 7 months after the last dose. Males: Use effective contraception during treatment and for 4 months after the last dose if you have a female partner who could become pregnant. Breastfeeding There is no information regarding whether Lutathera is present in human breast milk or how it might affect a nursing infant. Because radiation exposure poses a risk of serious adverse reactions in infants, breastfeeding is not recommended during treatment and for 2.5 months after the final dose.

Q: What forms and strengths does Lutathera come in?

Dosage Forms Lutathera is a radiopharmaceutical supplied as a sterile, clear, colorless to slightly yellow solution. It is administered by a healthcare professional as an intravenous injection. Strengths This medication is provided in a single-dose vial. The strength is determined by the level of radioactivity at the time of calibration and administration: Each single-dose vial contains a total radioactivity of 7.4 GBq (200 mCi) at the time of injection. The concentration is 370 MBq/mL (10 mCi/mL) at the time of calibration.

Q: What is the FDA approval status of Lutathera?

FDA Approval History Lutathera (lutetium Lu 177 dotatate) was first approved by the U.S. Food and Drug Administration (FDA) in January 2018. It was the first peptide receptor radionuclide therapy (PRRT) approved to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which include tumors of the foregut, midgut, and hindgut. Expanded Pediatric Approval In April 2024, the FDA expanded the approval of Lutathera to include pediatric patients 12 years of age and older with somatostatin receptor-positive GEP-NETs. This expansion made it the first radiopharmaceutical approved for pediatric patients with these specific types of tumors. Regulatory Classification Lutathera is a prescription medication classified as a radiopharmaceutical. Due to its radioactive components, it is subject to specific regulatory requirements regarding its handling, storage, and administration. It must be administered by qualified healthcare professionals in clinical settings equipped for nuclear medicine. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this drug.

Question 1

What is Lutathera?

Accepted Answer

Lutathera is a radiopharmaceutical used in nuclear medicine therapy. It consists of a radioactive isotope linked to a targeting molecule that recognizes specific receptors on certain cells.

This targeted approach allows for the delivery of radiation directly to the site of a tumor to help control its growth while minimizing effects on healthy tissue.

Question 2

What is Lutathera used for?

Accepted Answer

Lutathera is used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Question 3

How does Lutathera work?

Accepted Answer

Targeted Therapy

Lutathera belongs to a class of drugs known as peptide receptor radionuclide therapy (PRRT). It works by combining a targeting molecule with a radioactive isotope to deliver treatment directly to cancer cells.

How It Targets Cancer

Many neuroendocrine tumors have a high number of proteins on their surface called somatostatin receptors. Lutathera is designed to recognize and bind specifically to these receptors. Once the drug attaches to the receptor, the cancer cell absorbs the medication.

Destroying Tumor Cells

After entering the cell, the radioactive part of the medicine, called lutetium-177, releases energy in the form of radiation. This radiation travels a short distance to damage the DNA within the tumor cell and nearby cells. This damage prevents the cancer cells from reproducing and eventually leads to cell death.

Question 4

What are the active ingredients in Lutathera?

Accepted Answer

The active ingredient in Lutathera is dotatate.

Question 5

What are the side effects of Lutathera?

Accepted Answer

Common side effects of Lutathera may include:

Nausea
Vomiting
Fatigue
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Lutathera?

Accepted Answer

Lutathera belongs to the radiolabeled somatostatin analog drug class.

Question 7

What is the dosage of Lutathera and how do I take it?

Accepted Answer

Administration

Lutathera is a radioactive drug given by a healthcare professional through an intravenous (IV) infusion into a vein. Because it contains radiation, it must be administered in a specialized facility, such as a nuclear medicine department or a radiology clinic, by staff trained in handling radioactive materials.

Treatment Schedule

The treatment usually consists of a series of infusions. These doses are spaced several weeks apart to allow the body to recover between treatments. Your healthcare provider will determine the exact schedule based on your specific condition and how you respond to the medication.

Preparation and Supportive Care

To help protect your kidneys and manage side effects, you will receive other medications along with Lutathera:

Anti-nausea medication: You will receive medicine to help prevent nausea and vomiting before the infusion begins.
Amino acid solution: You will receive an intravenous infusion of amino acids before, during, and after the Lutathera treatment. This solution helps protect your kidneys from the effects of radiation.

Missed Doses

If you miss an appointment for your infusion, contact your healthcare provider immediately to reschedule. It is important to follow the treatment timeline as closely as possible for the medication to be effective.

Question 8

Is Lutathera safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Lutathera is a radiopharmaceutical that can cause harm to a fetus. Due to the risk of radiation exposure, healthcare providers will typically verify that a patient is not pregnant before starting treatment. If you are pregnant or become pregnant during treatment, it is important to discuss the potential risks to the fetus with your medical team.

Patients of reproductive potential should use effective birth control during treatment and for a period of time after the final dose:

Females: Use effective contraception during treatment and for 7 months after the last dose.
Males: Use effective contraception during treatment and for 4 months after the last dose if you have a female partner who could become pregnant.

Breastfeeding

There is no information regarding whether Lutathera is present in human breast milk or how it might affect a nursing infant. Because radiation exposure poses a risk of serious adverse reactions in infants, breastfeeding is not recommended during treatment and for 2.5 months after the final dose.

Question 9

What forms and strengths does Lutathera come in?

Accepted Answer

Dosage Forms

Lutathera is a radiopharmaceutical supplied as a sterile, clear, colorless to slightly yellow solution. It is administered by a healthcare professional as an intravenous injection.

Strengths

This medication is provided in a single-dose vial. The strength is determined by the level of radioactivity at the time of calibration and administration:

Each single-dose vial contains a total radioactivity of 7.4 GBq (200 mCi) at the time of injection.
The concentration is 370 MBq/mL (10 mCi/mL) at the time of calibration.

Question 10

What is the FDA approval status of Lutathera?

Accepted Answer

FDA Approval History

Lutathera (lutetium Lu 177 dotatate) was first approved by the U.S. Food and Drug Administration (FDA) in January 2018. It was the first peptide receptor radionuclide therapy (PRRT) approved to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which include tumors of the foregut, midgut, and hindgut.

Expanded Pediatric Approval

In April 2024, the FDA expanded the approval of Lutathera to include pediatric patients 12 years of age and older with somatostatin receptor-positive GEP-NETs. This expansion made it the first radiopharmaceutical approved for pediatric patients with these specific types of tumors.

Regulatory Classification

Lutathera is a prescription medication classified as a radiopharmaceutical. Due to its radioactive components, it is subject to specific regulatory requirements regarding its handling, storage, and administration. It must be administered by qualified healthcare professionals in clinical settings equipped for nuclear medicine. There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with this drug.

Question 11

What should I know about Lutathera and cost?

Accepted Answer

Estimated Costs

Lutathera is a specialized radiopharmaceutical medication with a high list price. A single dose is estimated to cost approximately $58,000. However, the actual price paid by patients or insurance providers often varies significantly from the list price based on negotiated rates and coverage details.

Factors Affecting Price

Facility and Administration Fees: Because Lutathera must be administered in a specialized nuclear medicine setting, total costs include fees for the medical staff, radiation safety equipment, and facility use.
Insurance Coverage: Most private insurance plans, Medicare, and Medicaid typically cover Lutathera for its FDA-approved uses. Patients may still be responsible for out-of-pocket costs such as deductibles, copayments, or coinsurance.
Treatment Course: A standard treatment course usually involves four doses given every eight weeks. The total cost of therapy is determined by the completion of this full series.

Financial Assistance Programs

The manufacturer may provide patient assistance programs or co-pay assistance for eligible patients to help reduce out-of-pocket expenses. Patients are encouraged to consult with their healthcare provider or a financial counselor at their treatment center to identify available support options.

Lutathera

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Lutathera

Hospitals.net Disclosure